Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.44 |
| ▸ | TPH1 | P17752 | 2/20 | 0.36 |
| ▸ | MET | P08581 | 6/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4422266 | 0.85 | HTR6 (0.40) | HTR6TPH1METCA1CA2 | |
| SCHEMBL4414908 | 0.78 | PKM (0.48) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4412007 | 0.76 | MAPT (0.46) | CA1CA2CA9CA14THRB | |
| SCHEMBL13972868 | 0.76 | CA1 (0.41) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4412933 | 0.76 | CA1 (0.41) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4422235 | 0.75 | KDM4E (0.48) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4414625 | 0.74 | CA1 (0.45) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4418374 | 0.74 | FPR2 (0.42) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL4414666 | 0.73 | ALDH1A1 (0.40) | CA1CA2CA9CA14PARP1 | |
| SCHEMBL13972641 | 0.73 | GAA (0.40) | CA1CA2CA9CA14PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | HTR6 534/4885TPH1 1312/4885MET 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.